Sarepta Therapeutics (SRPT) Total Current Liabilities (2010 - 2026)

Sarepta Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $499.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 17.57% year-over-year to $499.2 million; the TTM figure through Mar 2026 stood at $499.2 million (down 17.57% YoY), while the FY2025 annual figure was $1.1 billion, up 49.69% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $499.2 million, down from $1.1 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $1.1 billion in Q4 2025, with the low at $450.7 million in Q3 2023.
• The 5-year median for Total Current Liabilities is $608.7 million (2024), against an average of $654.9 million.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 61.45% in 2022, then slipped 25.24% in 2023.
• Sarepta Therapeutics' Total Current Liabilities stood at $619.6 million in 2022, then increased by 5.5% to $653.7 million in 2023, then rose by 11.94% to $731.7 million in 2024, then soared by 49.69% to $1.1 billion in 2025, then tumbled by 54.43% to $499.2 million in 2026.
• Business Quant data shows SRPT's Total Current Liabilities at $499.2 million in Q1 2026, $1.1 billion in Q4 2025, and $921.4 million in Q3 2025.